Clinical Oncology

[The concept and use of placebo and nocebo in oncology]

VÉGH Éva1, BAKI Márta1

NOVEMBER 30, 2021

Clinical Oncology - 2021;8(4)

[Placebo and nocebo effects recognised through all of the history of medicine, and these effects can be found also in the field of oncology research and clinical practice. Placebo effect are more than the effects of an inert substance. Placebo benefits the health status because of the person’s belief and nocebo worsens the health status of the patient. Several psychological mechanisms are involved in placebo/nocebo effects; expectation, learning processes (classical conditioning and observational learning), reinforced expectations, personality traits of the patient and the health care provider. At the same time placebo effects rely on neurobiologic mechanism (neurotransmitters like dopamine, cholecystokinin, opioids and activation of specific brain areas). The use of placebo is an important methodological tool in oncological research and drug development. Inert substance can be associated with positive (placebo) and negative (nocebo) adverse event profiles also can modify the measured therapeutic effects in randomized clinical trials.]

AFFILIATIONS

  1. Dél-pesti Centrum Kórház, Országos Hematológiai és Infektológiai Intézet, Szent László telephely, Onkológiai Osztály

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[New systemic treatment possibilities in non-small cell lung cancer]

OSTOROS Gyula, BOGOS Krisztina

Clinical Oncology

[Gastrointestinal cancers: role of biomarkers and based on driven treatment of gastrointestinal cancers]

PAJKOS Gábor

[Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the precision medicine in oncology approach, targeted therapy and immune checkpoint inhibitors achieved radically change in treatment efficacy based on accumulation of knowledge on the genomic profiles of gastrointestinal tract cancer (GI). Advanced or disseminated poor risk GI cancer patients have had a better chance for that progression free and/or overall survival. Highly effective treatment needs to incorporate numerous molecular characteristic into clinics – expression of PD-L1, MSI (micro satellite instability)/dMMR (defective mismatch repair), TMB (tumor mutation burden), resistance mutation, insertions/deletions and other genomic alterations. This review aims to summarize predictive and prognostic biomarkers might suggested for precision oncology treatment of GI cancers.]

Clinical Oncology

[Microbiome and cancer]

MIKÓ Edit, BAI Péter

[Most compartments and organs of the human body are not sterile, bacterial DNA and RNA can be detected using next generation sequencing techniques. All bacterial DNA in a compartment is called the metagenome, all bacterial transcripts are termed metatranscriptome, while all bacterial species is coined the microbiome. The microbiome transforms in neoplastic diseases that is called the oncobiome. Most tumors are colonized by bacteria that supports tumor growth and development. Microbiome compartments distant to the tumors (as the microbiome of the gastrointestinal tract) can also undergo oncobiotic transformation. The metabolic capacity of the oncobiotic microbiome in the gastrointestinal tract is suppressed and the production of a large set of cytostatic and antimetastatic bacterial metabolites is blunted supporting cancer cells proliferation and metastasis. The microbiome of the gastrointestinal tract has pivotal role in setting the tolerance of the immune system against cancer cells, therefore, has prime importance in tumor immunity. Oncobiosis, by itself, cannot induce tumors, but can support tumor growth and metastasis formation. Bacteria have key role in the success of cytostatic therapy and in setting the side effect profile.]

Clinical Oncology

[Pancreas cancer: Therapeutic trials in metastatic disease]

SMITHY W. James , O’REILLY M. Eileen

Clinical Oncology

[Mechanisms of metastasis formation as potential therapeutic targets]

TÍMÁR József, SEBESTYÉN Anna, KOPPER László

[The end-stage of the tumor progression is the development of the metastatic disease. The biological basis of this progression is well known, however the exact molecular background of it is not. In this process the metastatic cancer cells develop maximal adaptation to extreme environmental clues and collaborative potential with wide array of host cells, accordingly the metastatization takes place in an organ specific manner. The metastases are different from the primary tumor but from each other as well, and this true for their genetic background as well. The ultrasensitive monitoring of this process is possible with the use of liquid biopsy and molecular tests. Till we don’t have organ metastasis specific therapeutic modalities similarly to bone metastases, the available modalities must be fine-tuned for metastatic disease and not for the primary tumor. ]

All articles in the issue

Related contents

Clinical Neuroscience

Somatosensory amplification absorption contribute to electrosensitivity

KÖTELES Ferenc, SIMOR Péter, SZEMERSZKY Renáta

Background - Two trait-like characteristics, somatosensory amplification and absorption, have been associated with symptom reports and idiopathic environmental intolerances in past research. Purpose - As the two constructs are not connected with each other, their independent contribution to symptom reports and electromagnetic hypersensitivity, as well as their interaction can be expected. Methods - On-line questionnaire. Patients - 506 college students completed an on-line questionnaire assessing absorption, somatosensory amplification, negative affect, somatic symptoms, and electromagnetic hypersensitivity. Results - Somatosensory amplification (β = 0.170, p < 0.001) and absorption (β = 0.128, p < 0.001) independently contributed to somatic symptoms after controlling for gender and negative affect (R2 = 0.347, p < 0.001). Similarly, somatosensory amplification (OR = 1.082, p < 0.05) and absorption (OR = 1.079, p < 0.01) independently contributed to electromagnetic hypersensitivity after controlling for somatic symptoms, gender, and negative affect (Nagelkerke R2 = 0.134, p < 0.001). However, no interaction effects were found. Discussion - Somatosensory amplification and absorption independently contribute to symptom reports and electromagnetic hypersensitivity. Conclusion - The findings suggest that psychological mechanisms underlying symptom reports and electromagnetic hypersensitivity might be heterogeneous.

Lege Artis Medicinae

[Functional genomics - Potentials, hopes, and post genomic realism]

FALUS ANDRÁS, SZALAI Csaba, TÓTH Sára

[This paper provides an overview on major elements of the age of genomics: including the human genome programme, principles of gene chip technology and data management by bioinformatics. The manuscript provides examples from the fields of oncology, infectology and allergy. The possibility of ”in silico” research on computers is also presented with the shadows of the post-genomic era and the significance of changes in the biomedical paradigm.]

Clinical Oncology

[Invasive endoscopy in oncology]

MADÁCSY László

[Recent advances in interventional gastrointestinal endoscopy have led to a large variety of new diagnostic and minimally invasive endoscopic surgical procedures in oncological patients. Endoscopic ultrasound with the possibility of fi ne needle aspiration is currently one of the most accurate imaging technology for adequate staging of gastrointestinal cancers including oesophageal, gastric, rectal and pancreatic cancer. Endoscopic mucosal resection and endoscopic submucosal dissection offers a minimal invasive endoscopic treatment modality as an alternative for laparoscopic surgery for patients with early intramucosal neoplasias, fl at adenomas and laterally spreading tumors of the oesophagus, stomach, duodenum and colorectum. Self-expandable metal stents are now readily available for endoscopic palliation of different type of malignant gastrointestinal obstructions including oesophageal, duodenal, colonic and biliary stenosis. These recent developments of interventional gastrointestinal endoscopy lead to more precise and accurate tumor staging and more effective oncological therapy for patients with gastrointestinal cancers.]

Lege Artis Medicinae

[Hormone replacement therapy from a gynaeco oncological point of view]

BŐSZE Péter

[In Hungary, hormone replacement therapy (HRT) has been used more extensively in the last few years. The benefits of HRT in cardio vascular diseases, osteoporosis and quality of life have been well established. Breast cancer and endometrial carcinoma have been considered as contraindications for HRT. A reappraisal of this practice is necessary since we have no evidence that HRT may adversely influence the outcome of these tumours, al though this is theoretically possible since the effect of estrogens on occult metastases is unknown. The relationship between replacement therapy and the uterine sarcomas is of particular concern. HRT is safe in patients successfully treated for carcinoma of the vulva, vagina, uterine cervix and in those with ovarian cancer. Experience suggests that estrogen can also be used safely in women treated previously for endometrial cancer. As far as breast cancer is concerned, it appers logical to discuss the risk-benefit considerations with our patients before embarking on using HRT. Consultation with a gynaecological oncologist prior to HRT in patients with endometrial and/or breast cancer is strongly recommended. ]

Journal of Nursing Theory and Practice

[Attitude towards death, psychosomatic and pszichological status of nurses working in hospice care and oncology unit]

NAGY Rebeka, NÉMETH Anikó

[Aim of the research: The aim of the research was to examine the fear of death, the attitudes towards death, the way of processing death, related to the workplace and to assess the burn out and psychosomatic symptoms among oncology nurses and hospice care workers. Research and sampling methods: To execute our research self-developed surveys were distributed online and printed (N=116) in July-August 2015, completed with a control group, as well. For data analysis we used SPSS version 19.0 with the following statistical tests: Chi square test, independent two sample t-test, Spearman rank correlation and variance analysis (p<0,05). Results: Oncology nurses had slightly more positive attitudes towards death, with significant (p=0,034) proneness to concentrate on positive events too, in case of death of their patients, and tend to attend Bálint groups more often (p=0,017), than nurses working in other unists. In the latter group psychosomatic symptoms were more frequent (p=0,032). No significant differences (p=0,234) were found between the groups in cumulative scale of fear of death. Fear of death had great effect on appearance of psychosomatic symptoms (p=0,011) and the extent of burn out (p=0,001). Conclusions: There were no significant differences in fear of death between oncology nurses and hospise care workers.]